세계의 H2 수용체 길항제 시장 보고서(2025년)

H2 receptor antagonists are a class of medications that block histamine receptors in the stomach, reducing acid production to treat conditions such as acid reflux, ulcers, and gastroesophageal reflux disease (GERD). These drugs work by inhibiting the H2 receptors on parietal cells in the stomach lining, which are responsible for secreting gastric acid.

The main drug classes of H2 receptor antagonists include cimetidine, ranitidine, famotidine, and nizatidine. Cimetidine is an H2 receptor antagonist that reduces stomach acid production by blocking histamine H2 receptors on the gastric parietal cells. These drugs are indicated for conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, Zollinger-Ellison syndrome, and others. They are administered through various routes, including oral, intravenous, and intramuscular. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others. The primary end users include hospitals, clinics, and home care settings.

The H2 receptor antagonist market research report is one of a series of new reports from The Business Research Company that provides H2 receptor antagonist market statistics, including the H2 receptor antagonist industry global market size, regional shares, competitors with the H2 receptor antagonist market share, detailed H2 receptor antagonist market segments, market trends, and opportunities, and any further data you may need to thrive in the H2 receptor antagonist industry. This H2 receptor antagonist market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The H2 receptor antagonist market size has grown strongly in recent years. It will grow from $4.08 billion in 2024 to $4.32 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be attributed to the rising prevalence of peptic ulcers, widespread use of over-the-counter antacids, increasing diagnoses of gastroesophageal reflux disease (GERD), strong adoption in hospital settings, and a rising incidence of gastrointestinal disorders.

The H2 receptor antagonist market size is expected to see strong growth in the next few years. It will grow to $5.35 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The projected growth in the forecast period is driven by rising cases of lifestyle-related digestive disorders, increasing demand for non-prescription gastrointestinal treatments, a growing geriatric population with chronic acid issues, expanding availability of generic formulations, and the development of pediatric-friendly formulations. Key trends expected in the forecast period include the development of extended-release formulations, integration with digital health monitoring tools, innovation in pediatric dosage forms, combination therapies with probiotics, and advances in compound stability for hot climates.

The increasing incidence of gastrointestinal diseases is expected to drive the growth of the H2 receptor antagonist market. Gastrointestinal diseases are conditions that affect the digestive tract, including infections, inflammation, and disorders of the stomach and intestines. The rise in gastrointestinal diseases is largely attributed to unhealthy dietary habits and the increasing consumption of processed foods, which can disrupt gut health and lead to digestive disorders such as acid reflux, irritable bowel syndrome (IBS), and ulcers. H2 receptor antagonists address these conditions by blocking histamine receptors in the stomach, reducing acid production, and alleviating symptoms such as acid reflux, ulcers, and gastritis. For example, in January 2023, the American Cancer Society (ACS) reported a 3.18% increase in gastrointestinal cancer cases in the United States, rising from 338,090 in 2022 to 348,840 in 2023. As a result, the growing incidence of gastrointestinal diseases is driving the expansion of the H2 receptor antagonist market.

Companies in the H2 receptor antagonist market are focusing on developing innovative solutions, such as novel drug delivery systems, to improve the efficacy, convenience, and patient compliance of acid-suppressing treatments. Novel drug delivery systems are advanced technologies designed to release therapeutic agents in a controlled, targeted, and sustained manner for enhanced efficacy and better patient adherence. For instance, in June 2022, Zydus Lifesciences Limited, an India-based pharmaceutical company, launched Famotidine ODT, an orally disintegrating tablet for treating acid-related disorders such as GERD. This formulation allows patients, especially those with difficulty swallowing, to take the medication without water, improving convenience and compliance. Zydus highlighted that this innovation supports better treatment outcomes by making the medication easier to use and providing faster relief. The adoption of such delivery systems is helping to drive growth in the H2 receptor antagonist market by enhancing the therapeutic experience and accessibility for patients.

In October 2023, Amgen Inc., a US-based biotechnology company, acquired Horizon Therapeutics plc for $27.8 billion. This acquisition aims to strengthen Amgen's position in rare diseases and immunology by expanding its portfolio with Horizon's innovative therapies and global commercial capabilities. Horizon Therapeutics, an Ireland-based company, manufactures H2 receptor antagonists, enhancing Amgen's footprint in the gastrointestinal and inflammation treatment market.

Major players in the h2 receptor antagonist market are Pfizer Inc., Sanofi S.A., Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Apotex Inc., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Hikma Pharmaceuticals plc, Lupin Ltd., Zydus Lifesciences Limited, Torrent Pharmaceuticals Limited, Accord Healthcare Limited.

North America was the largest region in the H2 receptor antagonist market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in H2 receptor antagonist report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the H2 receptor antagonist market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The H2 receptor antagonist market consists of sales of tegoprazan and lansoprazole. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

H2 Receptor Antagonist Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on h2 receptor antagonist market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for h2 receptor antagonist ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The h2 receptor antagonist market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Cimetidine; Ranitidine; Famotidine; Nizatidine
• 2) By Route of Administration: Oral; Intravenous; Intramuscular
• 3) By Indication: Gastroesophageal Reflux Disease (GERD); Peptic Ulcers; Zollinger-Ellison Syndrome; Other Indications
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• 5) By End-User: Hospitals; Clinics; Home Care Settings
• Companies Mentioned: Pfizer Inc.; Sanofi S.A.; Abbott Laboratories; Novartis AG; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. H2 Receptor Antagonist Market Characteristics

3. H2 Receptor Antagonist Market Trends And Strategies

4. H2 Receptor Antagonist Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global H2 Receptor Antagonist Growth Analysis And Strategic Analysis Framework

• 5.1. Global H2 Receptor Antagonist PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global H2 Receptor Antagonist Market Growth Rate Analysis
• 5.4. Global H2 Receptor Antagonist Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global H2 Receptor Antagonist Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global H2 Receptor Antagonist Total Addressable Market (TAM)

6. H2 Receptor Antagonist Market Segmentation

• 6.1. Global H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cimetidine
• Ranitidine
• Famotidine
• Nizatidine
• 6.2. Global H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gastroesophageal Reflux Disease (GERD)
• Peptic Ulcers
• Zollinger-Ellison Syndrome
• Other Indications
• 6.3. Global H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Intramuscular
• 6.4. Global H2 Receptor Antagonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
• 6.5. Global H2 Receptor Antagonist Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Home Care Settings

7. H2 Receptor Antagonist Market Regional And Country Analysis

• 7.1. Global H2 Receptor Antagonist Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global H2 Receptor Antagonist Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific H2 Receptor Antagonist Market

• 8.1. Asia-Pacific H2 Receptor Antagonist Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China H2 Receptor Antagonist Market

• 9.1. China H2 Receptor Antagonist Market Overview
• 9.2. China H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India H2 Receptor Antagonist Market

• 10.1. India H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan H2 Receptor Antagonist Market

• 11.1. Japan H2 Receptor Antagonist Market Overview
• 11.2. Japan H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia H2 Receptor Antagonist Market

• 12.1. Australia H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia H2 Receptor Antagonist Market

• 13.1. Indonesia H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea H2 Receptor Antagonist Market

• 14.1. South Korea H2 Receptor Antagonist Market Overview
• 14.2. South Korea H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe H2 Receptor Antagonist Market

• 15.1. Western Europe H2 Receptor Antagonist Market Overview
• 15.2. Western Europe H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK H2 Receptor Antagonist Market

• 16.1. UK H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany H2 Receptor Antagonist Market

• 17.1. Germany H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France H2 Receptor Antagonist Market

• 18.1. France H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy H2 Receptor Antagonist Market

• 19.1. Italy H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain H2 Receptor Antagonist Market

• 20.1. Spain H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe H2 Receptor Antagonist Market

• 21.1. Eastern Europe H2 Receptor Antagonist Market Overview
• 21.2. Eastern Europe H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia H2 Receptor Antagonist Market

• 22.1. Russia H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America H2 Receptor Antagonist Market

• 23.1. North America H2 Receptor Antagonist Market Overview
• 23.2. North America H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA H2 Receptor Antagonist Market

• 24.1. USA H2 Receptor Antagonist Market Overview
• 24.2. USA H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada H2 Receptor Antagonist Market

• 25.1. Canada H2 Receptor Antagonist Market Overview
• 25.2. Canada H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America H2 Receptor Antagonist Market

• 26.1. South America H2 Receptor Antagonist Market Overview
• 26.2. South America H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil H2 Receptor Antagonist Market

• 27.1. Brazil H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East H2 Receptor Antagonist Market

• 28.1. Middle East H2 Receptor Antagonist Market Overview
• 28.2. Middle East H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa H2 Receptor Antagonist Market

• 29.1. Africa H2 Receptor Antagonist Market Overview
• 29.2. Africa H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. H2 Receptor Antagonist Market Competitive Landscape And Company Profiles

• 30.1. H2 Receptor Antagonist Market Competitive Landscape
• 30.2. H2 Receptor Antagonist Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. H2 Receptor Antagonist Market Other Major And Innovative Companies

• 31.1. Takeda Pharmaceutical Company Limited
• 31.2. Eli Lilly and Company
• 31.3. Viatris Inc.
• 31.4. Teva Pharmaceutical Industries Limited
• 31.5. Boehringer Ingelheim International GmbH
• 31.6. Sun Pharmaceutical Industries Limited
• 31.7. Apotex Inc.
• 31.8. Aurobindo Pharma Limited
• 31.9. Dr. Reddy's Laboratories Limited
• 31.10. Cipla Limited
• 31.11. Hikma Pharmaceuticals plc
• 31.12. Lupin Ltd.
• 31.13. Zydus Lifesciences Limited
• 31.14. Torrent Pharmaceuticals Limited
• 31.15. Accord Healthcare Limited

32. Global H2 Receptor Antagonist Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The H2 Receptor Antagonist Market

34. Recent Developments In The H2 Receptor Antagonist Market

35. H2 Receptor Antagonist Market High Potential Countries, Segments and Strategies

• 35.1 H2 Receptor Antagonist Market In 2029 - Countries Offering Most New Opportunities
• 35.2 H2 Receptor Antagonist Market In 2029 - Segments Offering Most New Opportunities
• 35.3 H2 Receptor Antagonist Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer